{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:12:22Z","timestamp":1790622742729,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T00:00:00Z","timestamp":1558224000000},"content-version":"am","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"Intramural Research Program of the National Institute on Drug Abuse (NIDA)","doi-asserted-by":"publisher","award":["DA00523"],"award-info":[{"award-number":["DA00523"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["DA06241"],"award-info":[{"award-number":["DA06241"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","award":["DA07242"],"award-info":[{"award-number":["DA07242"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001744","name":"Mayday Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001744","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH\/NCI Cancer Center","doi-asserted-by":"publisher","award":["CA008748"],"award-info":[{"award-number":["CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"NIMH Psychoactive Drug Screening Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.neuropharm.2017.08.016","type":"journal-article","created":{"date-parts":[[2017,8,12]],"date-time":"2017-08-12T11:18:42Z","timestamp":1502536722000},"page":"101-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"special_numbering":"PA","title":["Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace"],"prefix":"10.1016","volume":"134","author":[{"given":"Michael H.","family":"Baumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susruta","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Le Rouzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Hunkele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Uprety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan L.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Xian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavril W.","family":"Pasternak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.08.016_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/jat\/16.1.36","article-title":"Fentanyl receptor assay. II. utilization of a radioreceptor assay for the analysis of fentanyl analogs in urine","volume":"16","author":"Alburges","year":"1992","journal-title":"J.\u00a0Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12954-015-0088-4","article-title":"Why the FUSS (Fentanyl Urine Screen Study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada","volume":"12","author":"Amlani","year":"2015","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.annemergmed.2016.06.014","article-title":"Fentanyl and a novel synthetic opioid U-47700 masquerading as street \u201cNorco\u201d in central California: a case report","volume":"69","author":"Armenian","year":"2017","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/syn.10277","article-title":"Functional analysis of MOR-1 splice variants of the mouse mu opioid receptor gene Oprm","volume":"51","author":"Bolan","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/dta.1686","article-title":"The new drug phenomenon","volume":"6","author":"Brandt","year":"2014","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib6","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1021\/jm00150a017","article-title":"Factors affecting binding of trans-N-[2-(methylamino)cyclohexyl]benzamides at the primary morphine receptor","volume":"28","author":"Cheney","year":"1985","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib7","series-title":"Emerging Threat Report Mid-year 2016 [DEA Emerging Trends Report]","author":"Drug Enforcement Administration","year":"2016"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib8","series-title":"Schedules of Controlled Substances: Temporary Placement of Butyryl Fentanyl and Beta-hydroxythiofentanyl into Schedule I [Docket No. DEA-434F]","author":"Drug Enforcement Administration","year":"2016"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib9","series-title":"Schedules of Controlled Substances: Temporary Placement of U-47700 into Schedule I [Docket No. DEA-440]","author":"Drug Enforcement Administration","year":"2016"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib10","series-title":"Counterfeit Prescription Pills Containing Fentanyls, a Global Threat [DEA Intelligence Brief]","author":"Drug Enforcement Administration","year":"2016"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/dta.1984","article-title":"The first reported fatality associated with the synthetic opioid 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (U-47700) and implications for forensic analysis","volume":"8","author":"Elliott","year":"2016","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib12","series-title":"EMCDDA\u2013europol Joint Report on a New Psychoactive Substance: 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (\u2018MT-45\u2019) [Risk Assessment Report]","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2014"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJMp1615145","article-title":"Addressing the fentanyl threat to public health","volume":"376","author":"Frank","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1254\/jjp.28.505","article-title":"Analgesic activity and opiate receptor binding of 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine","volume":"28","author":"Fujimura","year":"1978","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.15585\/mmwr.mm6533a2","article-title":"Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths - 27 states, 2013-2014","volume":"65","author":"Gladden","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib16","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jamainternmed.2016.4310","article-title":"Counterfeit medications and fentanyl","volume":"176","author":"Green","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/syn.21914","article-title":"Mediation of buprenorphine analgesia by a combination of traditional and truncated mu opioid receptor splice variants","volume":"70","author":"Grinnell","year":"2016","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1476-5381.1985.tb11112.x","article-title":"Determination of the receptor selectivity of opioid agonists in the Guinea-pig ileum and mouse vas deferens by use of beta-funaltrexamine","volume":"86","author":"Hayes","year":"1985","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/15563650.2014.943908","article-title":"MT-45, a new psychoactive substance associated with hearing loss and unconsciousness","volume":"52","author":"Helander","year":"2014","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib20","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/bjd.15174","article-title":"Acute skin and hair symptoms followed by severe, delayed eye complications in subjects using the synthetic opioid MT-45","volume":"176","author":"Helander","year":"2017","journal-title":"Br. J. Dermatol"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11419-007-0039-1","article-title":"Studies on 1-(2-phenethyl)-4-(N-propionylanilino)piperidine (fentanyl) and its related compounds. VI. Structure\u2013analgesic activity relationship for fentanyl, methyl-substituted fentanyls and other analogues","volume":"26","author":"Higashikawa","year":"2008","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nsmb.3014","article-title":"PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome","volume":"22","author":"Kroeze","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib23","first-page":"144","article-title":"Structure activity studies of two classes of beta-amino-amides: the search for kappa-selective opioids","volume":"90","author":"Loew","year":"1988","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib24","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1172\/JCI81070","article-title":"Mediation of opioid analgesia by a truncated 6-transmembrane GPCR","volume":"125","author":"Lu","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib25","first-page":"1","article-title":"The growing problem of new psychoactive substances (NPS)","volume":"32","author":"Madras","year":"2017","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib26","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1016\/j.bmcl.2011.05.008","article-title":"Generation of novel radiolabeled opiates through site-selective iodination","volume":"21","author":"Majumdar","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib27","doi-asserted-by":"crossref","first-page":"19778","DOI":"10.1073\/pnas.1115231108","article-title":"Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects","volume":"108","author":"Majumdar","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib28","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00213-017-4600-2","article-title":"Genetic dissociation of morphine analgesia from hyperalgesia in mice","volume":"234","author":"Marrone","year":"2017","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jat\/bkv138","article-title":"An acute butyr-fentanyl fatality: a case report with postmortem concentrations","volume":"40","author":"McIntyre","year":"2016","journal-title":"J.\u00a0Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib30","first-page":"709","article-title":"Analysis of novel synthetic opioids U-47700, U-50488 and furanyl fentanyl by LC-MS\/MS in postmortem casework","volume":"40","author":"Mohr","year":"2016","journal-title":"J.\u00a0Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib31","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1021\/jm00246a014","article-title":"Studies on 1-substituted 4-(1,2-diphenylethyl)piperazine derivatives and their analgesic activities","volume":"18","author":"Natsuka","year":"1975","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib32","series-title":"Dainippon Pharmaceutical Co. Ltd., Assignee. 1-substituted-4-(1,2-diphenylethyl)-piperazine Derivatives and Their Salts and the Preparation Thereof","author":"Nishimura","year":"1976"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib33","series-title":"World Drug Report","doi-asserted-by":"crossref","DOI":"10.18356\/603a2a94-en","author":"United Nations Office of Drug and Crime","year":"2016"},{"issue":"Suppl 1","key":"10.1016\/j.neuropharm.2017.08.016_bib34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0024-3205(83)90534-9","article-title":"(1,2-Diphenylethyl) piperazines as potent opiate-like analgesics; the unusual relationships between stereoselectivity and affinity to opioid receptor","volume":"33","author":"Nozaki","year":"1983","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib35","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1073\/pnas.0811586106","article-title":"Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions","volume":"106","author":"Pan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib36","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neuropharm.2013.03.039","article-title":"Opioids and their receptors: are we there yet?","volume":"76","author":"Pasternak","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jat\/bkw048","article-title":"Two fatal intoxications involving butyryl fentanyl","volume":"40","author":"Poklis","year":"2016","journal-title":"J.\u00a0Anal. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/ADM.0000000000000324","article-title":"Misuse of novel synthetic opioids: a deadly new trend","volume":"11","author":"Prekupec","year":"2017","journal-title":"J.\u00a0Addict. Med."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib39","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths - United States, 2010-2015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/mol.51.1.87","article-title":"Mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy","volume":"51","author":"Selley","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3109\/15563650.2014.983239","article-title":"Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45","volume":"53","author":"Siddiqi","year":"2015","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib42","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugalcdep.2016.11.033","article-title":"A\u00a0review: fentanyl and non-pharmaceutical fentanyls","volume":"171","author":"Suzuki","year":"2017","journal-title":"Drug Alcohol. Depend."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib43","series-title":"The Upjohn Company, Assignee. Analgesic N-(2-aminocycloaliphatic)benzamides","author":"Szmuszkowicz","year":"1978"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib44","series-title":"Fentanyl: China's Deadly Export to the United States","author":"US-China Economic and Security Review Commission","year":"2017"},{"key":"10.1016\/j.neuropharm.2017.08.016_bib45","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ejmech.2013.09.031","article-title":"Novel 6\u00e2-acylaminomorphinans with analgesic activity","volume":"69","author":"V\u00e1radi","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib46","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/acschemneuro.5b00153","article-title":"Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior","volume":"6","author":"V\u00e1radi","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib47","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.2174\/092986709788682074","article-title":"Fentanyl analogs: structure-activity-relationship study","volume":"16","author":"Vuckovi\u0107","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.08.016_bib48","first-page":"579","article-title":"Evaluation of new compounds for opioid activity: 1987 annual report","volume":"81","author":"Woods","year":"1988","journal-title":"NIDA Res. Monogr."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817303830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817303830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T13:38:08Z","timestamp":1618148288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817303830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":48,"alternative-id":["S0028390817303830"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.08.016","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}